BMY faces a compounding patent cliff with Revlimid already eroded, Eliquis Medicare negotiation hitting 2026, and Opdivo LOE approaching. The Karuna acquisition and Cobenfy schizophrenia launch are promising but cannot fill the revenue hole alone. Debt load from recent deals constrains further M&A. Cost cuts buy time but not growth.
Thesis reviewed May 29, 2026
Bristol-Myers Squibb Company is headquartered in United States, which is currently showing elevated risk signals.
🇺🇸United States82EXITView United States risk detail →💊Pharma0NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| AZN | AstraZeneca PLC | 50 | +11% | ↓0% | EARLY |
| JNJ | Johnson & Johnson | 50 | +8% | ↓0% | NEUTRAL |
| REGN | Regeneron Pharmaceuticals Inc. | 50 | -16% | ↓0% | AVOID |
| TAK | Takeda Pharmaceutical Company Limited | 50 | +10% | ↓0% | NEUTRAL |
| LLY | Eli Lilly and Company | 50 | +24% | ↓0% | EARLY |
| PFE | Pfizer Inc. | 50 | +6% | ↓0% | NEUTRAL |
| NVO | Novo Nordisk A/S | 50 | +15% | ↓0% | EARLY |
Investors who hold BMY may also have indirect exposure through these country funds.
Eliquis Medicare negotiated price 56% below WAC takes effect Jan 2026
Cobenfy launch tracking below consensus on access barriers
BMY announces second round of headcount cuts
Estimates · Yahoo Finance · Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Alan Armstrong | Buy | $1k–$15k | Mar 27, 26 | ||
| Mike KellyPA | Buy | Unknown amount | May 7, 26 | ||
| Julie JohnsonTX | D | Buy | $1k–$15k | Dec 18, 25 | +2.0% |
| Julia LetlowLA | R | Buy | $1k–$15k | Oct 23, 24 | +3.3% |
| Julia LetlowLA | R | Buy | $1k–$15k | Apr 28, 25 | +3.3% |
| Gilbert CisnerosCA | D | Buy | $1k–$15k | Dec 19, 25 | +3.6% |
| Thomas H Tuberville | Sell | $1k–$15k | Apr 15, 25 | +31.1% | |
| John JamesMI | R | Buy | $1k–$15k | Nov 10, 23 | +24.2% |
| John JamesMI | R | Buy | $1k–$15k | Jan 18, 24 | +24.2% |